Latest Post

The Top Ingredients to Look For in Menopausal Skin-Care Probiotics: Solving Poor Digestive Health How to Do Double Leg Lift in Pilates? Tips, Technique, Correct Form, Benefits and Common Mistakes Top 5 Emerging Skincare Markets in 2022: Brazil, China, India, Mexico and South Africa – Market Summary, Competitive Analysis and Forecast to 2025 – ResearchAndMarkets.com Kelvin Harrison Jr. Is Growing with the Flow

The following are the top rated Healthcare stocks according to Validea’s Book/Market Investor model based on the published strategy of Joseph Piotroski. This value-quant strategy screens for high book-to-market stocks, and then separates out financially sound firms by looking at a host of improving financial criteria.

EMERGENT BIOSOLUTIONS INC (EBS) is a small-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Joseph Piotroski is 80% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Emergent BioSolutions, Inc. is a life sciences company focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats (PHTs). The Company is focused on five PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases; travel health; public health crises (such as the opioid crisis and the COVID-19 pandemic); acute, emergency, and community care. Its business lines include Medical Countermeasures (MCM), Commercial and CDMO. MCM focuses primarily on procurement of MCM products and procured product candidates by domestic and international government customers. It provides solutions for public health threats through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers. The Company also offers a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers.

The following table summarizes whether the stock meets each of this strategy’s tests. Not all criteria in the table below receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy’s criteria.

BOOK/MARKET RATIO: PASSPORT
RETURN ON ASSETS: PASSPORT
CHANGE IN RETURN ON ASSETS: FAIL
CASH FLOW FROM OPERATIONS: PASSPORT
CASH COMPARED TO NET INCOME: PASSPORT
CHANGE IN LONG-TERM DEBT/ASSETS PASSPORT
CHANGE IN CURRENT RATIO: PASSPORT
CHANGE IN SHARES OUTSTANDING: PASSPORT
CHANGE TO LARGE MARGIN: FAIL
CHANGE IN ASSET TURNOVER: PASSPORT

Detailed Analysis of EMERGENT BIOSOLUTIONS INC

Full Guru Analysis for EBS>

Full Factor Report for EBS>

TELADOC HEALTH INC (TDOC) is a mid-cap value stock in the healthcare facilities industry. The rating according to our strategy based on Joseph Piotroski is 80% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Teladoc Health, Inc. provides virtual healthcare services. The Company operates in the health services segment. The Company provides virtual access to care with a portfolio of services and solutions, which includes various medical subspecialties from non-urgent, episodic needs, such as flu and upper respiratory infections, to chronic, complicated medical conditions, such as hypertension, cancer and congestive heart failure. It provides provide virtual healthcare services on a business-to-business (B2B) basis to its clients including employers, health plans, hospitals and health systems, and insurance and financial services companies spanning the global healthcare landscape and provide services to consumers directly and through channel partners. The Company’s consumer brands, including Teladoc, Livongo, Advance Medical, Best Doctors, BetterHelp and HealthiestYou, provides access to advice and resolution for an array of healthcare needs.

The following table summarizes whether the stock meets each of this strategy’s tests. Not all criteria in the table below receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy’s criteria.

BOOK/MARKET RATIO: PASSPORT
RETURN ON ASSETS: FAIL
CHANGE IN RETURN ON ASSETS: PASSPORT
CASH FLOW FROM OPERATIONS: PASSPORT
CASH COMPARED TO NET INCOME: PASSPORT
CHANGE IN LONG-TERM DEBT/ASSETS PASSPORT
CHANGE IN CURRENT RATIO: PASSPORT
CHANGE IN SHARES OUTSTANDING: FAIL
CHANGE TO LARGE MARGIN: PASSPORT
CHANGE IN ASSET TURNOVER: PASSPORT

Detailed Analysis of TELADOC HEALTH INC

Full Guru Analysis for TDOC>

Full Factor Report for TDOC>

ZIMVIE INC (ZIMV) is a small-cap value stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Joseph Piotroski is 80% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: ZimVie Inc. is a medical technology company. The Company develops, manufactures, and markets a portfolio of products and solutions designed to treat a range of spine pathologies and support dental tooth replacement and restoration procedures. The Company’s operations are managed on a products basis and include two operating segments: the spine products segment, and the dental products segment. Its spine products segment focused on designing, manufacturing, and distributing medical devices and surgical instruments to deliver solutions for individuals with back or neck pain caused by degenerative conditions, deformities, tumors, or traumatic injury of the spine. Its product portfolio includes Mobi-C Cervical Disc and the Tether device. Its dental products segment is focused on designing, manufacturing and/or distributing of dental implant solutions. Its products include T3 Implant, Tapered Screw-Vent Implant System, Trabecular Metal Dental Implant, and BellaTek Encode Impression System.

The following table summarizes whether the stock meets each of this strategy’s tests. Not all criteria in the table below receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy’s criteria.

BOOK/MARKET RATIO: PASSPORT
RETURN ON ASSETS: FAIL
CHANGE IN RETURN ON ASSETS: PASSPORT
CASH FLOW FROM OPERATIONS: PASSPORT
CASH COMPARED TO NET INCOME: PASSPORT
CHANGE IN LONG-TERM DEBT/ASSETS PASSPORT
CHANGE IN CURRENT RATIO: PASSPORT
CHANGE IN SHARES OUTSTANDING: PASSPORT
CHANGE TO LARGE MARGIN: FAIL
CHANGE IN ASSET TURNOVER: PASSPORT

Detailed Analysis of ZIMVIE INC

Full Guru Analysis for ZIMV>

Full Factor Report for ZIMV>

INOTIV INC (NOTV) is a small-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Joseph Piotroski is 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Inotiv, Inc. is an international contract research company that is focused on providing drug discovery and development services and analytical instruments. The Company focuses on providing drug developers with scientific research and analytical instrumentation. The Company operates through two segments, including Contract Research Services and Research Products. The Contract Research Services segment provides screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance and quality control testing. The Research Products segment offers two principal product lines, including analytical products and in vivo sampling products. Analytical products consist of liquid chromatographic and electrochemical instruments with associated accessories. In vivo sampling products consist of the Culex family of automated in vivo sampling and dosing instruments.

The following table summarizes whether the stock meets each of this strategy’s tests. Not all criteria in the table below receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy’s criteria.

BOOK/MARKET RATIO: PASSPORT
RETURN ON ASSETS: PASSPORT
CHANGE IN RETURN ON ASSETS: PASSPORT
CASH FLOW FROM OPERATIONS: PASSPORT
CASH COMPARED TO NET INCOME: FAIL
CHANGE IN LONG-TERM DEBT/ASSETS FAIL
CHANGE IN CURRENT RATIO: PASSPORT
CHANGE IN SHARES OUTSTANDING: FAIL
CHANGE TO LARGE MARGIN: PASSPORT
CHANGE IN ASSET TURNOVER: FAIL

Detailed Analysis of INOTIV INC

Full Guru Analysis for NOTV>

Full Factor Report for NOTV>

TILRAY INC (TLRY) is a small-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Joseph Piotroski is 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Tilray Brands, Inc., formerly Tilray, Inc., is a global cannabis-lifestyle consumer packaged goods company. The Company operates through four segments: cannabis business, distribution business, beverage alcohol business and wellness business. The cannabis business segment is engaged in the cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The distribution business segment is engaged in the purchase and resale of pharmaceutical and wellness products to customers. The beverage alcohol business segment is focused on the production, distribution, and sale of beverage alcohol products. The wellness business segment offers production, marketing, and distribution of hemp-based food and cannabidiol (CBD) products. The Company operates in Canada, the United States, Europe, Australia, and Latin America.

The following table summarizes whether the stock meets each of this strategy’s tests. Not all criteria in the table below receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy’s criteria.

BOOK/MARKET RATIO: PASSPORT
RETURN ON ASSETS: FAIL
CHANGE IN RETURN ON ASSETS: PASSPORT
CASH FLOW FROM OPERATIONS: FAIL
CASH COMPARED TO NET INCOME: PASSPORT
CHANGE IN LONG-TERM DEBT/ASSETS PASSPORT
CHANGE IN CURRENT RATIO: PASSPORT
CHANGE IN SHARES OUTSTANDING: FAIL
CHANGE TO LARGE MARGIN: PASSPORT
CHANGE IN ASSET TURNOVER: FAIL

Detailed Analysis of TILRAY INC

Full Guru Analysis for TLRY>

Full Factor Report for TLRY>

More details on Validea’s Joseph Piotroski strategy

About Joseph Piotroski: Piotroski isn’t your typical Wall Street big shot. In fact, he’s not even a professional investor. He’s a good old numbers-crunching accountant and college professor. But in 2000, shortly after he started teaching at the University of Chicago’s Graduate School of Business, Piotroski published a groundbreaking paper in the Journal of Accounting Research entitled “Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers”. In it, Piotroski laid out an accounting-based stock-selection/shorting method that produced a 23 percent average annual back-tested return from 1976 through 1996 — more than double the S&P 500’s gain during that time. Piotroski’s findings were reported in major financial publications like SmartMoney. Today, he teaches accounting at Stanford University’s Graduate School of Business.

About Validea: Validea is an investment research service that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here

The views and opinions expressed in are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: